Biosimilar Naming Compromise In Europe May Protect Fledgling MAb Competitors
This article was originally published in The Pink Sheet Daily
Executive Summary
The European generics industry is open to a compromise to INN differentiation that could protect the potentially explosive biosimilar MAbs market by using a suffix on the established name.